AstraZeneca touts benefit of camizestrant over Faslodex in breast cancer
hapabapa


AstraZeneca's (NASDAQ:AZN) said that its experimental onocologic camizestrant led to statistically significant improvement in progression-free survival (PFS) versus Faslodex (fulvestrant) in women with metastatic breast cancer.
A phase 2 study examined the drug at two dose levels in post-menopausal patients with ER-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy.

Results showed that camizestrant reduced the risk of disease progression or death by 42% at a 75mg dose and 33% at a 150mg dose compared to Faslodex, which is the current standard of care selective estrogen receptor degrader therapy in the population.
Median PFS at the 75mg dose was 7.2 versus 3.7 months. At the 150mg dose, it was 7.7 versus 3.7 months.
AstraZeneca (AZN) first released top-line details about the SERENA-2 trial in October.